Exploring the role of anti-angiogenic therapies in prostate cancer： results from the phase 3 trial of sunitinib

作     者：Himisha Beltran Gurveen Kaur Carmen Garcias de Espana Scott T Tagawa 

作者机构：Division of Hematology and Medical Oncology Weill Cornell Medical College New York USA 

出 版 物：《Asian Journal of Andrology》 (亚洲男性学杂志（英文版）)

年 卷 期：2014年第16卷第4期

页      面：568-569页

核心收录：

学科分类：0710[理学-生物学] 090603[农学-临床兽医学] 1002[医学-临床医学] 07[理学] 08[工学] 09[农学] 0906[农学-兽医学] 071007[理学-遗传学] 0901[农学-作物学] 0836[工学-生物工程] 090102[农学-作物遗传育种] 

主　　题：TYROSINE KINASE INHIBITOR SU11248 MEN 

摘      要：Prostate cancer is aleading cause of cancer death in men. Despite recent advancesin our understanding and treatment of advanced disease, no systemic therapy is curative and new therapies are needed. Targeting angiogenesis is an attractive therapeutic strategy, as angiogenic pathways are upregulated in prostate tumors similar to other malignancies due to imbalance of pro- and anti-angiogenic factors secreted by tumor,